PM
EVOK

Precept Management’s Evoke Pharma EVOK Stock Holding History

Precept Management’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-660
Closed -$243K – 60
2017
Q2 		$243K Hold
660
– – 0.15% 67
2017
Q1 		$295K Buy
+660
New +$270K 0.29% 43

Other funds holding EVOK

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Precept Management's EVOK Position: Q3 2017 in Review

Precept Management sold out of Evoke Pharma (EVOK) in Q3 2017, closing a stake of 660 shares — an estimated $243K sold.

Precept Management first reported a position in EVOK in Q1 2017 and held it in 2 quarters. The position peaked at $295K in Q1 2017. 21 funds tracked by Wall St. Rank hold EVOK as of Q3 2017.

  • Precept Management reported no remaining Evoke Pharma position as of Q3 2017 after selling out during the quarter.
  • Precept Management sold 660 Evoke Pharma shares in Q3 2017, an estimated $243K.
  • Precept Management first reported a position in Evoke Pharma in Q1 2017 and held it in 2 quarters.
  • Precept Management's Evoke Pharma position peaked at $295K in Q1 2017.
  • 21 funds tracked by Wall St. Rank held Evoke Pharma as of Q3 2017.

Based on Precept Management's 13F filing for Q3 2017, filed 14 Nov 2017.